Drug Search Results
More Filters [+]

Elafibranor

Alternative Names: elafibranor, gft505
Latest Update: 2024-04-05
Latest Update Note: News Article

Product Description

Mechanisms of Action: PPAR-d Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Priority Review - Cholestatic Liver Disease *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Genfit
Company Location: LOOS I0 59120
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Elafibranor

Countries in Clinic: Argentina, Belgium, Brazil, Canada, Chile, France, Germany, Italy, Portugal, South Africa, Spain, Switzerland, Turkey, United Kingdom, United States

Active Clinical Trial Count: 7

Highest Development Phases

Phase 3: Biliary Cirrhosis|Cholangitis|Liver Cirrhosis

Phase 2: Cholangitis, Sclerosing

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ELFIDENCE

P3

Recruiting

Liver Cirrhosis|Cholangitis|Biliary Cirrhosis

2030-10-18

70%

2019-004941-34

P3

Active, not recruiting

Cholangitis|Biliary Cirrhosis

2028-01-09

2022-002695-37

P2

Active, not recruiting

Cholangitis, Sclerosing

2026-03-10

ELMWOOD

P2

Recruiting

Cholangitis, Sclerosing

2024-12-16

24%

Recent News Events